Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Justice Department Investigating Novation; BD Faces Whistleblower Lawsuit

This article was originally published in The Gray Sheet

Executive Summary

BD maintains it is not the target of a U.S. Department of Justice criminal investigation of Novation, despite being subpoenaed to provide evidence in the case against the group purchasing organization

You may also be interested in...



Medtronic whistleblowers

Firm receives copy of second civil qui tam complaint Sept. 2 on "allegations under the False Claims Act" similar to charges a September 2003 whistleblower brought against its Sofamor Danek spinal division, according to Medtronic's recent 110-Q filing. The Department of Justice is investigating "certain payments and other services provided to physicians by Medtronic" that may have been "improper inducements under the federal anti-kickback statute." The case is under seal at Memphis federal court. In its quarterly report filed with SEC Aug. 13, BD revealed it has been cited by a qui tam complaint, also on the False Claims Act (2"The Gray Sheet" Aug. 30, 2004, p. 22)...

Coronavirus Notebook: UK On Cusp Of First Vaccine Approval, Moderna To File mRNA-1273 in US & EU

Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.

UsernamePublicRestriction

Register

OM006145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel